January 7, 2014 Coalition Against Major Diseases/European Medicines Agency Biomarker Qualification Of Hippocampal Volume For Enrichment Of Clinical Trials In Predementia Stages Of Alzheimer’s Disease
January 4, 2014 Operationalizing Hippocampal Volume as an Enrichment Biomarker for Amnestic Mild Cognitive Impairment Trials: Effect of Algorithm, Test-Retest Variability, and Cut Point on Trial Cost, Duration, and Sample Size
October 8, 2013 High Variability and Lack of Change on the ADAS-Cog: Placebo Analyses of the CODR Database
September 10, 2013 C-Path cosponsors Alzheimer’s workshop C-Path cosponsors workshop on combination drug development for Alzheimer’s disease Combination therapy development has been
January 8, 2013 Understanding Placebo Responses In Alzheimer’s Disease Clinical Trials From The Literature Meta-data And CAMD Database
July 10, 2013 U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease
